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Dear Editor,
It is important for patients who are on a waiting list for
organ transplant to maintain an adequate nutritional status in
order to undergo surgery in the best possible condition. For
patients who have cystic fibrosis (CF) and CF-related
diabetes (CFRD), this objective may be difficult to obtain.
Increased caloric requirements in response to energy
consumed, use of hyperglycaemic therapies, low appetite
and irregularity of meals can all affect the patients’
metabolic control and precarious nutritional status [1]. The
presence of diabetes and a bad nutritional status negatively
influence the 5-year survival of CF people [2].
To treat CFRD, multiple daily insulin injections (MDII)
have been recommended [3]. However, MDII regimen is
sometimes badly accepted by the patient [1,4].
Compared to conventional insulin injection regimens,
continuous subcutaneous insulin infusion (CSII) provides a
closer approximation of normal plasma glycaemic profiles
and allows more flexibility in the timing of meals and snacks
[5,6]. Its use is increasingly widespread among children and
adults with Type 1 diabetes, but currently no reports of its use
in CF patients with CFRD awaiting transplant are available.
Our experience with the use of CSII in a 23-year-old CF
patient (DF508/unk) with CFRD, on MDII for 5 years, who
was awaiting lung and liver transplantation, has shown itself
to be encouraging.
In the period from the onset of CFRD (Oct. 2000) to the
beginning of CSII (Sept. 2004) the patient’s mean blood
glucose level was 241.3 mg/dL (SD 34.3), mean body weight
was 52.7 kg (SD 1.4), mean BMI was 18.6 kg/m2 (SD 0.5)
and mean FEV1 (% of predicted) was 39% (SD 0.03). His
insulin requirement rose from 8 IU/day (0.15 IU/kg/day) at
the onset of CFRD to 56 IU/day (1.07 IU/kg/day) before
starting CSII. The patient’s compliance to MDII was
problematic.
In the 6-month period from the start of CSII to the
transplantation, the mean blood glucose level was 137.5 mg/
dL (SD 3.5). The mean body weight increased to 54.8 kg
(SD 1.2), mean BMI was 19.4 kg/m2 (SD 0.4). Mean FEV1
continued to decrease down to 34%. The insulin require-
ment changed from 35 IU/day (0.6 IU/kg/day) at the start of
CSII to 51 IU/day (0.9 IU/kg/day) before transplantation.1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.09.002No episodes of hypo- or hyperglycaemia occurred during
the CSII period. The patient showed appreciation for this
method which induced better compliance in administration
of insulin at meals and snacks.
The use of CSII in our experience provided improved
nutritional condition and metabolic control of the patient
awaiting transplant. CSII can be useful for CF patients with
CFRD, especially those with the most compromised respira-
tory and metabolic condition. CSII provides improved
metabolic control, furthering compliance through better
flexibility in insulin therapy in patients with low appetite, with
disorderly timing of meals or requiring a hypercaloric diet.
After transplantation, it will be interesting to observe
how CSII helps counteract the hyperglycaemic effect of
anti-rejection drugs.References
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